Stifel Upgrades Tandem Diabetes Care and Downgrades Insulet Amid Tubeless Pump Market Trends
Analyst Jonathan Block at Stifel has adjusted his ratings for two major players in the insulin pump market. Tandem Diabetes Care (TNDM) was upgraded from Hold to Buy, while rival Insulet Corporation (PODD) received a downgrade. The rating changes are driven by recent survey results that highlight shifting consumer trends and preferences within the tubeless insulin pump segment. The move suggests a change in market sentiment regarding which company is better positioned to capture upcoming demand in this specific niche.
